BioCardia (BCDA) said Monday it received a Japanese patent titled "Radial and Transendocardial Delivery Catheter" for its catheter technology Helix Biotherapeutic Delivery System.
The patent, valid until on or after Sept. 30, 2034, covers catheters designed to deliver biological therapies directly to targeted areas of the heart, the company said.
The patent's claims include BioCardia's helical needle-tipped catheter technology platform, which is used in the administration of cardiac treatments, it added.
Shares of BioCardia were down 3% in recent trading.
Price: 2.54, Change: -0.08, Percent Change: -3.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.